孟鲁司特对哮喘患儿胸腺和活化调节趋化因子的干预作用

目的探讨孟鲁司特对哮喘患儿胸腺和活化调节趋化因子（TARC）的干预作用，探寻儿童哮喘新的治疗方案。方法100例哮喘患儿随机分两组，哮喘孟鲁司特治疗组（50例）予口服孟鲁司特，哮喘布地奈德治疗组（50例）予布地奈德雾化吸入，同期在该院儿科住院的急性支气管炎无喘患儿50例为对照组雾化吸入生理盐水，检测各组用药前及用药后血清、痰液TARC的含量。结果用药前哮喘组TARC的含量明显高于对照组（P〈0．05），用药后孟鲁司特治疗组与布地奈德治疗组TARC的含量均明显下降（P〈0．05），下降幅度与对照组比较差异有统计学意义（P〈0．05），孟鲁司特治疗组与布地奈德治疗组TARC的下降幅度无明显差异（P〉0．05）。结论TARC参与了儿童哮喘气道炎症的发生，孟鲁司特可减轻哮喘患儿TARC的水平，缓解患儿哮喘症状，且用药方便、安全性高。

Intervention effect of montelukast on thymus and activation-regulated chemokine in children with asthma

Objective To study the intervention effect of montelukast on thymus and activation-regulated chemokine(TARC) in the children with asthma.Methods 100 children with asthma were randomly divided into montelukast (LTRA) group ( n = 50) and budesonide (BUD) group ( n = 50), the LTRA group was treated with montelukast, the BUD group was treated with budesonide,50 children without asthma as control group were inhaled NS.Before and after 7 days treatment,the asthma symptoms, FEV1,concentration of TARC were measured.Results Before treatment,the concentration of TARC in asthma group was significantly higher than control group (P < 0.05 ).After treatment, the concentration of TARC in BUD group and LTRA group was significandy decreased( P < 0.05 ), but the difference between these two groups was not significantl( P > 0.05 ), the concentration of TARC in control group was not significantly decreased(P > 0.05 ) ;the symptoms were better after treatment in BUD group and LTRA group,(P <0,05) ,and the pulmonary function was significantly improved after treatment in BUD group and LTRA group ( P < 0.05 ).Conclusion TARC was the important factor in children asthma.Montelukast could block the production of TARC ,and was more convenient and safe for children asthma.